Loading…

Current state of treatment for primary cutaneous melanoma

The incidence of malignant melanoma has been rising steadily for the last 30 years. Through physician and patient education, surveillance of high-risk individuals, and biopsy of any suspicious lesions, more lesions are being diagnosed earlier, where there is a high cure rate. Unfortunately many pati...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental medicine 2004-10, Vol.4 (2), p.65-77
Main Authors: Chung, E S, Sabel, M S, Sondak, V K
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c367t-260b1728724d432d9e29550ecededa36f8cfbdbf1e46cbda027aec5d2a91440d3
cites
container_end_page 77
container_issue 2
container_start_page 65
container_title Clinical and experimental medicine
container_volume 4
creator Chung, E S
Sabel, M S
Sondak, V K
description The incidence of malignant melanoma has been rising steadily for the last 30 years. Through physician and patient education, surveillance of high-risk individuals, and biopsy of any suspicious lesions, more lesions are being diagnosed earlier, where there is a high cure rate. Unfortunately many patients will still present with thicker lesions or nodal involvement, which carries a significantly worse prognosis. Over the past decade, there have been several changes in the management of primary cutaneous melanoma. These have stemmed from novel surgical approaches, a new understanding of melanoma biology, and randomized clinical trials designed to improve outcome and decrease the morbidity of therapy. This article will review the clinical evidence behind the current treatment recommendations for primary cutaneous melanoma as well as some of the emerging data on innovative immunologic-approaches to melanoma treatment.
doi_str_mv 10.1007/s10238-004-0040-5
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67237053</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67237053</sourcerecordid><originalsourceid>FETCH-LOGICAL-c367t-260b1728724d432d9e29550ecededa36f8cfbdbf1e46cbda027aec5d2a91440d3</originalsourceid><addsrcrecordid>eNpdUE1LxDAUDKK46-oP8CLFg7fqS9I0yVGW9QMWvOg5pMkr7NKPNUkP_ntbWhA8PN7jMTPMDCG3FB4pgHyKFBhXOUAxDeTijKyp0DTXgqnz5VZKw4pcxXgEoEJxuCQrKkrJdMHXRG-HELBLWUw2YdbXWQpoUzu96j5kp3BobfjJ3JBsh_0QsxYb2_WtvSYXtW0i3ix7Q75edp_bt3z_8fq-fd7njpcy5ayEikqmJCt8wZnXyLQQgA49esvLWrm68lVNsShd5S0wadEJz6ymRQGeb8jDrHsK_feAMZn2EB02zezHjEm4BMFH4P0_4LEfQjd6M4xDqZjS5QiiM8iFPsaAtVkSGgpmKtXMpZqx0GnAiJFztwgPVYv-j7G0yH8B8CFyCA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230682896</pqid></control><display><type>article</type><title>Current state of treatment for primary cutaneous melanoma</title><source>Springer Link</source><creator>Chung, E S ; Sabel, M S ; Sondak, V K</creator><creatorcontrib>Chung, E S ; Sabel, M S ; Sondak, V K</creatorcontrib><description>The incidence of malignant melanoma has been rising steadily for the last 30 years. Through physician and patient education, surveillance of high-risk individuals, and biopsy of any suspicious lesions, more lesions are being diagnosed earlier, where there is a high cure rate. Unfortunately many patients will still present with thicker lesions or nodal involvement, which carries a significantly worse prognosis. Over the past decade, there have been several changes in the management of primary cutaneous melanoma. These have stemmed from novel surgical approaches, a new understanding of melanoma biology, and randomized clinical trials designed to improve outcome and decrease the morbidity of therapy. This article will review the clinical evidence behind the current treatment recommendations for primary cutaneous melanoma as well as some of the emerging data on innovative immunologic-approaches to melanoma treatment.</description><identifier>ISSN: 1591-8890</identifier><identifier>EISSN: 1591-9528</identifier><identifier>DOI: 10.1007/s10238-004-0040-5</identifier><identifier>PMID: 15672943</identifier><identifier>CODEN: CEMLBA</identifier><language>eng</language><publisher>Italy: Springer Nature B.V</publisher><subject>Adjuvants, Immunologic - therapeutic use ; Cancer Vaccines - therapeutic use ; Clinical trials ; Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use ; Humans ; Immunology ; Interferon-alpha - therapeutic use ; Lymphatic Metastasis ; Melanoma - secondary ; Melanoma - therapy ; Recombinant Proteins ; Skin Neoplasms - pathology ; Skin Neoplasms - therapy ; Tumors</subject><ispartof>Clinical and experimental medicine, 2004-10, Vol.4 (2), p.65-77</ispartof><rights>Copyright Springer-Verlag 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c367t-260b1728724d432d9e29550ecededa36f8cfbdbf1e46cbda027aec5d2a91440d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15672943$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chung, E S</creatorcontrib><creatorcontrib>Sabel, M S</creatorcontrib><creatorcontrib>Sondak, V K</creatorcontrib><title>Current state of treatment for primary cutaneous melanoma</title><title>Clinical and experimental medicine</title><addtitle>Clin Exp Med</addtitle><description>The incidence of malignant melanoma has been rising steadily for the last 30 years. Through physician and patient education, surveillance of high-risk individuals, and biopsy of any suspicious lesions, more lesions are being diagnosed earlier, where there is a high cure rate. Unfortunately many patients will still present with thicker lesions or nodal involvement, which carries a significantly worse prognosis. Over the past decade, there have been several changes in the management of primary cutaneous melanoma. These have stemmed from novel surgical approaches, a new understanding of melanoma biology, and randomized clinical trials designed to improve outcome and decrease the morbidity of therapy. This article will review the clinical evidence behind the current treatment recommendations for primary cutaneous melanoma as well as some of the emerging data on innovative immunologic-approaches to melanoma treatment.</description><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Clinical trials</subject><subject>Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use</subject><subject>Humans</subject><subject>Immunology</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Lymphatic Metastasis</subject><subject>Melanoma - secondary</subject><subject>Melanoma - therapy</subject><subject>Recombinant Proteins</subject><subject>Skin Neoplasms - pathology</subject><subject>Skin Neoplasms - therapy</subject><subject>Tumors</subject><issn>1591-8890</issn><issn>1591-9528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpdUE1LxDAUDKK46-oP8CLFg7fqS9I0yVGW9QMWvOg5pMkr7NKPNUkP_ntbWhA8PN7jMTPMDCG3FB4pgHyKFBhXOUAxDeTijKyp0DTXgqnz5VZKw4pcxXgEoEJxuCQrKkrJdMHXRG-HELBLWUw2YdbXWQpoUzu96j5kp3BobfjJ3JBsh_0QsxYb2_WtvSYXtW0i3ix7Q75edp_bt3z_8fq-fd7njpcy5ayEikqmJCt8wZnXyLQQgA49esvLWrm68lVNsShd5S0wadEJz6ymRQGeb8jDrHsK_feAMZn2EB02zezHjEm4BMFH4P0_4LEfQjd6M4xDqZjS5QiiM8iFPsaAtVkSGgpmKtXMpZqx0GnAiJFztwgPVYv-j7G0yH8B8CFyCA</recordid><startdate>20041001</startdate><enddate>20041001</enddate><creator>Chung, E S</creator><creator>Sabel, M S</creator><creator>Sondak, V K</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20041001</creationdate><title>Current state of treatment for primary cutaneous melanoma</title><author>Chung, E S ; Sabel, M S ; Sondak, V K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c367t-260b1728724d432d9e29550ecededa36f8cfbdbf1e46cbda027aec5d2a91440d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Clinical trials</topic><topic>Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use</topic><topic>Humans</topic><topic>Immunology</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Lymphatic Metastasis</topic><topic>Melanoma - secondary</topic><topic>Melanoma - therapy</topic><topic>Recombinant Proteins</topic><topic>Skin Neoplasms - pathology</topic><topic>Skin Neoplasms - therapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chung, E S</creatorcontrib><creatorcontrib>Sabel, M S</creatorcontrib><creatorcontrib>Sondak, V K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>PHMC-Proquest健康医学期刊库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Proquest Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chung, E S</au><au>Sabel, M S</au><au>Sondak, V K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current state of treatment for primary cutaneous melanoma</atitle><jtitle>Clinical and experimental medicine</jtitle><addtitle>Clin Exp Med</addtitle><date>2004-10-01</date><risdate>2004</risdate><volume>4</volume><issue>2</issue><spage>65</spage><epage>77</epage><pages>65-77</pages><issn>1591-8890</issn><eissn>1591-9528</eissn><coden>CEMLBA</coden><abstract>The incidence of malignant melanoma has been rising steadily for the last 30 years. Through physician and patient education, surveillance of high-risk individuals, and biopsy of any suspicious lesions, more lesions are being diagnosed earlier, where there is a high cure rate. Unfortunately many patients will still present with thicker lesions or nodal involvement, which carries a significantly worse prognosis. Over the past decade, there have been several changes in the management of primary cutaneous melanoma. These have stemmed from novel surgical approaches, a new understanding of melanoma biology, and randomized clinical trials designed to improve outcome and decrease the morbidity of therapy. This article will review the clinical evidence behind the current treatment recommendations for primary cutaneous melanoma as well as some of the emerging data on innovative immunologic-approaches to melanoma treatment.</abstract><cop>Italy</cop><pub>Springer Nature B.V</pub><pmid>15672943</pmid><doi>10.1007/s10238-004-0040-5</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1591-8890
ispartof Clinical and experimental medicine, 2004-10, Vol.4 (2), p.65-77
issn 1591-8890
1591-9528
language eng
recordid cdi_proquest_miscellaneous_67237053
source Springer Link
subjects Adjuvants, Immunologic - therapeutic use
Cancer Vaccines - therapeutic use
Clinical trials
Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use
Humans
Immunology
Interferon-alpha - therapeutic use
Lymphatic Metastasis
Melanoma - secondary
Melanoma - therapy
Recombinant Proteins
Skin Neoplasms - pathology
Skin Neoplasms - therapy
Tumors
title Current state of treatment for primary cutaneous melanoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A08%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20state%20of%20treatment%20for%20primary%20cutaneous%20melanoma&rft.jtitle=Clinical%20and%20experimental%20medicine&rft.au=Chung,%20E%20S&rft.date=2004-10-01&rft.volume=4&rft.issue=2&rft.spage=65&rft.epage=77&rft.pages=65-77&rft.issn=1591-8890&rft.eissn=1591-9528&rft.coden=CEMLBA&rft_id=info:doi/10.1007/s10238-004-0040-5&rft_dat=%3Cproquest_cross%3E67237053%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c367t-260b1728724d432d9e29550ecededa36f8cfbdbf1e46cbda027aec5d2a91440d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=230682896&rft_id=info:pmid/15672943&rfr_iscdi=true